Reiji Mijizhu Monoclonal Antibody Injection officially launched in China.

On April 18th, Eli Lilly China announced that its innovative drugs for treating inflammatory bowel disease, Entyvio and Entyvio (vedolizumab), have been launched in China. Entyvio and Entyvio are inhibitors targeting the IL-23p19 subunit, approved by the China National Medical Products Administration in February 2026 for the treatment of moderate to severe active ulcerative colitis and moderate to severe active Crohn's disease in adults.